Reply
We appreciate the comment of Fingerhut and associates regarding our study of photodynamic therapy (PDT) with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy (PCV). They raise the question of the timing of the intravitreal bevacizumab injection in the combination therapy for PCV. We address this issue herein.